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Docosahexaenoic acid (DHA; 22:6co3) is one of the major omega-3 
polyunsaturated fatty acids (co-3 PUFAs) found in fish oils that has been reported with 
various health beneficial properties. In this study, DHA from a cultural microalga, 
Crypthecodinium cohnii, was used, which is free of environmental pollutants that 
have been frequently reported in fish oils. The effects and mechanisms of this 
microalgal DHA on inhibiting the tumor cell growth in vitro and in vivo were 
investigated. 
Results from the MTT study showed that the microalgal DHA reduced 
proliferation and viability of a variety of cancer cell lines from different organ sites 
and histological subtypes in vitro. Of the tested cancer cell lines, melanoma A3 75 was 
found to be the most responsive one, so it was selected as the cell model for further 
mechanistic studies. DHA reduced proliferation and survival of the melanoma cells as 
determined by BrdU incorporation assay and DNA-flow cytometric analysis. Low 
doses (below 80 |j.M) of DHA induced cell cycle arrest at G2/M and S phase, while 
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160 jiM DHA not only arrested cells in the cell cycle phases, but also induced 
apoptosis after 72 h of treatment. The proapoptotic effect of DHA was further 
supported by PARP cleavage in the Western blot analysis. Both the intrinsic and 
extrinsic apoptolic pathways were activated, as indicated by the activation of caspase 
8 and caspase 9. Activation of the intrinsic pathway was associated with the depletion 
of antiapoptotic Bcl-2 and the elevation of proapoptotic Bak; while the extrinsic 
pathway might be initiated by the elevation of death receptor DR4 and its ligand 
TRAIL. DHA also exhibited anticancer effect in vivo in the athymic nude mice model. 
Transplanted A375 solid tumors were regressed after treating the mice with DHA by 
gavage for 10 consecutive days. DHA reduced the tumor weight significantly by 57.1 
and 61.9 % of the control level at 50 and 200 mg/kg, respectively. No observable 
adverse effect of DHA was found during the treatment period. Preliminary results 
from the immunoblot analysis showed that the tumor regression in 50 mg/kg 
treatment was associated with elevated DR4, TRAIL and Bak and decreased Bcl-2, 
which were consistent to those findings in the in vitro study. 
In conclusion, DHA retards growth and induces cell death in A375 melanoma 
both in vitro and in vivo. It activates both the intrinsic and extrinsic apoptotic 
pathways in the cells by modulating some apoptotic proteins, such as the antiapoptotic 
Bcl-2 and proapoptotic Bak, DR4 and TRAIL. The results from this study provide a 
ii 
foundation for the future development of microalgal DHA as a chemotherapeutic 
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Chapter 1 Introduction 
Worldwide, approximately 10 million people are diagnosed with cancer annually 
and more than 6 million people die of the disease every year. Diet is thought to be one 
of the most important factors contributing to cancer risk (Kleihues et al” 2003). From 
the past epidemiological and clinical studies, it was found that population with high 
intake of fish for many years had a relatively low frequency of cancer occurrence. 
Many researches have attributed these beneficial effects to fish oil's high content of 
omega-3 polyunsaturated fatty acids (PUFAs). Docosahexaenoic acid (DHA; 22:6co3) 
is one of the major PUFAs that has been shown of having growth inhibitory properties 
on a variety of cancer cells both in vitro and in vivo. It is now recognized as an 
important niitraceutical with anticancer and various other health beneficial properties. 
Omega-3 PUFAs cannot be synthesized in our bodies, so we have to obtain these fatty 
acids from our diet particularly in fatty fish, fish oil or marine-based foods. However, 
environmental pollution has caused contamination and concentration of toxins in fish 
oils that make them no longer a clean and safe source. Cultured microalgae have 
recently been regarded as a cleaner and safer source of PUFAs. Hence, in this study, a 
number of studies were performed to investigate the effects and mechanisms of 
microalgal DHA on inhibiting the tumor cell growth. 
1 
1.1 Cancer 
"Cancer" is derived from the Greek word karkinos meaning "crab". It is a 
common term for all malignant tumors. Broadly speaking, cancer refers to a large 
group of diseases that arise in any of the body's tissues and that are characterized by 
the uncontrolled growth and spread of the abnormal cells. If the spread is not 
diagnosed and controlled, it may cause death. It is a growing health problem around 
the world. Because of its impact on human health and the hope that a cure might be 
developed, cancer has been the focus of a massive research for decades. These studies 
have led to a remarkable breakthrough in our understanding of the cellular and 
molecular basis of cancer, and had significant impact on either preventing the 
occurrence of or increasing the chances of surviving most cancers. 
1.1.1 Tumor development 
Carcinogenesis is a multistage process leading to cancer formation that 
includes the steps of initiation, promotion and progression. Initiation is a process 
whereby the chemical or its reactive metabolites cause a permanent change (mutation) 
in DNA of a target cell. The process is rapid and irreversible that involves a chain of 
extracellular and intracellular events. These include the initial uptake of or exposure 
to a carcinogenic agent, and its distribution and transport to organs and tissues where 
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metabolic activation and detoxification can occur. The initiated cells may remain 
latent until acted upon by promoting agents. In contrast to initiation, tumor promotion 
is a relatively lengthy and reversible process in which actively proliferating 
preneoplastic cells accumulate. Progression is the final stage of neoplastic 
transformation which involves the growth of a tumor with invasive and metastatic 
potential (Surh, 2003). 
The development of a malignant tumor involves progression of genetic alterations that 
make the cells increasingly less responsive to the body's normal regulatory machinery 
and better able to invade normal tissues. The genes that have implicated in 
carcinogenesis are divided into two broad categories: tumor suppressor genes and 
oncogenes. Tumor suppressor genes encode proteins that restrain cell growth and 
prevent cells from becoming malignant, including transcription factors, cell-cycle 
regulators, components that regulate signaling pathways and phosphatases. Most of 
the proteins encoded by tumor suppressor genes act as negative regulators of cell 
proliferation, so that their elimination promotes uncontrolled cell growth. Oncogenes, 
on the other hand, encode proteins that promote the loss of growth control and the 
conversion of a cell to a malignant state. They are derived from proto-oncogenes, 
which are genes that encode proteins having function in the normal cell. Most of them 
play a role in the control of cell growth, including growth stimulation by external 
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ligands, cellular signal transduction or progression through the cell cycle. Alterations 
ill both tumor suppressor genes and oncogenes were found in almost all tumors (Karp, 
2002). During this process the cell develops defects in growth control, resistance to 
cytotoxicity and defects in programmed cell death. 
1.1.2 Cell cycle 
Defects in cell cycle regulatory mechanism leading to uncontrolled cell 
proliferation are the properties of cancer cells that are different from normal ones. The 
control of cell division is critical to normal tissue structure and function. It is 
regulated by a complex interplay of many genes that control the cell cycle, with DNA 
replication and mitosis as the major checkpoints. The cell cycle is tightly regulated to 
minimize transmission of genetic damage to subsequent cell generation. Cancer may 
be perceived as the consequence of loss of cell cycle control and progressive genetic 
instability. The distinct molecular control of cell cycle progression between normal 
and cancer cells provide an useful conceptual framework to identify new potential 
targets for anti-neoplastic therapies (Hanahan and Weinberg, 2000; Kleihues et al., 
2003). 
Cell cycle refers to the set of ordered molecular and cellular processes during 
which genetic material is replicated and segregated between two newly generated 
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daughter cells via the process of mitosis. The cell has to progress orderly through a 
series of stages that by convention is subdivided into four phases: Gi, a phase during 
which the cell prepares to synthesize DNA; S, a period of DNA synthesis; G2, a 
period in which preparations are made for cell division; and M, the mitotic phase 
itself. Between divisions, the cell is said to be in interphase. The cell continues to 
grow throughout interphase with high metabolic activity. Cells in the body that are not 
actively dividing may be either terminally differentiated, and thus unable to re-enter 
the cell cycle, or in a state of temporary arrest called Go. (Fig. 1.1) (Becker et al., 
2000; Kamb, 1995). 
To maintain genetic stability, cells have evolved biochemical pathways that 
ensure completion of phase-specific events before passage into the next phase of the 
cell cycle. In response to cellular stress, activation of checkpoints at the Gi/S 
transition, S phase, G2/M transition, or mitosis are hypothesized to reduce the 
accumulation of mutations by blocking the replication of mutated DNA and by 
inhibiting the mitotic division of damaged chromosomes. These pathways are called 
cell-cycle checkpoints. At each checkpoint, conditions within the cell determine 
whether or not the cell will proceed to the next stage of the cycle (Hartwell and 
We inert, 1989). There are three main checkpoints in the eukaryotic cell cycle. The 
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Fig 1.1 The Cell Cycle 
The cell cycle can be divided into two stages: M phase and interphase. M 
phase includes the successive stages of mitosis and cytokinesis. Interphase 
is made up of the S phase (the period of DNA replication) and two "gap" 
phases, called Gi and G2. Three of the main checkpoints in the cell cycle are 
also indicated with red marks, which determine whether or not the cell 
proceeds through the rest of the cycle. If conditions are not satisfactory at 
Gi or G2 checkpoints, the cell exits the cycle and goes into a resting state. 
(Modified from Becker et al., 2000) 
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ability to pass through the restriction point is controlled to a large extent by 
extracellular growth factors which make the decision to proceed, pause, or exit the 
cell cycle. Cells that have successfully passed through the restriction point are 
committed to S phase, whereas those that have not passed this point can exit the cell 
cycle and enter a non-dividing, quiescent Go phase. The second checkpoint, G2 
checkpoint, is located at the boundary between G2 and M phase. The G2/M transition 
is prevented by DNA damage and by incompletely replicated DNA. This checkpoint 
prevents chromosome segregation if the chromosome set is not intact. In some cell 
types, the cell cycle can be indefinitely arrested in a resting state at this point if cell 
division is not necessary. The third checkpoint is spindle assembly checkpoint, which 
is at the junction between metaphase and anaphase inside the M phase. Before cells 
can pass through the spindle assembly checkpoint and begin anaphase, all the 
chromosomes must be properly attached to the spindle. If the two chromatids that 
make up each chromosome are not properly attached to opposite spindle poles, the 
cell cycle is temporarily arrested at this point. This checkpoint guarantees that each of 
the newly forming daughter cells would receive a complete set of chromosomes. 
Elimination of the cell cycle checkpoints may have severe effects for the cell, such as 
the generation of mutations and subsequent transformation or cell death (Becker el aL, 
2000; Hartwell and Kastan, 1994). 
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Progression through each phase of the cell cycle is tightly regulated and 
involves the expression and rapid degradation of the cyclin-dependent kinase (cdk) 
complex. Cdks are a group of serine/threonine kinases that form active heterodimeric 
complexes following binding to their regulatory subunits, cyclins. In general, the 
levels of cdks are relatively constant throughout the cell cycle, while the cyclin levels 
vary substantially as the cell cycle progresses. Cyclin-cdk complexes are regulated by 
phosphorylation and protein interaction events that tightly control the timing and 
extent of cdk activation. The cell cycle activities during mid G| are accomplished 
primarily by cdk4 and cdk6 associated with the D-type cyclins (Dl , D2 and D3). The 
Gi/S transition is driven by the activity of the cyclin E-cdk2 and cyclin A-cdk2 
complexes. The transition from G2 to M is driven by the activity of cyclin A-cdkl 
complex, cyclin B-cdkl complex and APC/C (anaphase promoting complex / 
cyclosonie). APC/C is active during mitosis, which is responsible for destroying or 
ubiquinating proteins, such as seciirin and mitotic cyclins, to initiate anaphase and 
promote exit from mitosis. Destruction of cyclins A and B is a key factor in the 
activation of cdkl and the transition of the cell from mitosis back into Gi (Becker el 
al, 2000; Kamb, 1995; Karp, 2002). 
Many of the effects of cyclin-cdk complexes are mediated through 
phosphorylation of retinoblastoma protein (pRb). pRb controls the progression of cell 
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cycle by regulating the activities of transcription factors, most importantly, E2F2 and 
E2F3. In a hypophosphorylated state, pRb physically associates with these 
transcriptional factors and blocks their ability to activate the gene expression of 
products necessary for cell cycle progression. Once phosphorylated, pRb loses much 
or all of its growth inhibitory power and permits the advance into late Gi, and hence, 
into the remainder of the cell cycle. Rb is identified as a tumor suppressor gene, its 
protein is contributed to restrain cell growth and prevent cells from becoming 
malignant. The absence or inactivation of Rb gene can lead to cancer (Giacinti and 
Giordano, 2006). 
1.1.3 Apoptosis 
The ability of tumor cell populations to expand in number is determined not 
only by the rate of cell proliferation but also by the rate of cell attrition. Cells have an 
intrinsic mechanism of self destruction called programmed cell death or apoptosis 
(Kerr et al., 1972). It is a key regulator of homeostasis to tightly control cell numbers 
and tissue size, which is essential for embryonic development, immune-system 
function and tissue homeostasis in multicellular organisms. However, tumor cells 
often have faulty apoptotic pathways. The defects in apoptotic machinery can make 
cancer cells resistant to therapy since apoptosis is one of the main contributors to the 
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cytotoxic effect of conventional chemotherapeutic drugs and irradiation (Hengartner, 
2000; Kaufmann and Gores, 2000). The understanding of apoptosis has provided the 
basis for novel targeted therapies that can induce death in cancer cells or sensitize 
them to established cytotoxic agents and radiation therapy (Igney and Krammer, 
2002). 
The process of apoptosis can be described by reference to distinct phases, 
termed "initiation" and "execution" respectively. The initiation phase includes all the 
signaling pathways that culminate in commitment to cell death. Critical to apoptosis 
signaling are the "initiator" caspases (caspase 8, 9 and 10) whose role is to activate 
the more abundant "effector/executioner" caspases (caspase 3, 6 and 7) which, in turn, 
brings about the morphological change indicative of apoptosis. The characteristics of 
apoptosis include cell membrane blebbing, cell shrinkage, chromatin condensation, 
and DNA fragmentation without eliciting a significant inflammatory response. 
Apoptosis is distinct from necrosis in which the cells suffer a major insult, leading to 
a loss of membrane integrity, swelling and disruption of the cells (Kanduc el al., 2002; 
Wyllie, 1997). Apoptosis terminates with the recognition of cellular remains and their 
elimination by the engulfing activity of surrounding cells (Savill and Fadok, 2000). 
Most of the morphological changes in apoptosis are caused by a set of death 
proteases. These death proteases are homologous to each other, and are part of a large 
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protein family known as the caspases (Alnemri et al., 1996). Not all caspases are 
involved in apoptosis. All known caspases possess an active-site cysteine, which 
cleaves substrates after the aspartic acid residue. All caspases are expressed as 
proenzymes that contain three domains: a NH2-terminal domain, a large subunit, and a 
small subunit. Activation involves proteolytic processing between domains, followed 
by association of the large subunit and the small subunits to form a heterodimer. 
Caspases can be activated either autocatalytically or in a cascade by other caspases. In 
apoptosis, caspases function in both cell disassembly (effectors) and in initiating this 
disassembly in response to proapoptotic signals (initiators). The caspases that have 
been well described are caspases 3, 6, 7，8, 9 and 10. Caspases 3，6 and 7 are effector 
caspases that attack critical cytoplasmic proteins. The effector caspases are activated 
by the initiator caspases, caspases 8, 9 and 10. Usually, once the initiator caspases are 
being activated, the downstream effector caspases will be activated in a cascade-like 
pattern (Hengartner, 2000; Thornberry and Lazebnik, 1998). 
Apoptosis occurs through two main pathways. One of them is the extrinsic or 
death receptor pathway, which is triggered by the death ligands and their receptors. 
The other pathway is the intrinsic or mitochondrial pathway. Stimulation of the 
intrinsic pathway by DNA damage or cellular stress leads to the release of cytochrome 
c from mitochondria. Both pathways converge to a final common pathway involving 
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the activation of a cascade of caspases that cleave regulatory and structural molecules, 
which leads to the biochemical and morphological changes that are characteristic of 
apoptosis (Fig. 1.2) (Heiigartner, 2000). 
I 
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Fig. 1.2 The Two Main Apoptotic Pathways 
The extrinsic pathway is induced by ligauds binding to death receptors on 
the cell surface, which in turn leads to the activation of initiator caspase 8 or 
10. On the other hand, the intrinsic pathway is triggered by apoptotic stimuli 
and is mediated through mitochondrial release of apoptogenic molecules, 
such as cytochrome c, which lead to the activation of initiator caspase 9. 
Both of the pathways converge to the activation of effector caspases that 
cleave the death substrates, which eventually results in apoptosis. There is a 
crosstalk between these two pathways. Cleavage of Bid by caspase 8 
activates the mitochondrial pathway after apoptosis induction through death 
receptors. (Modified from Igiiey and Krammer, 2002) 
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1.1.3.1 The extrinsic pathway 
This pathway comprises several protein members including death receptors, 
ligands, Fas-associated death domain (FADD), and caspase 8 or 10, which ultimately 
activate the rest of the downstream caspases leading to apoptosis. Activation of the 
extrinsic pathway is initiated with the ligation of cell surface receptors called death 
receptors. Death receptors are members of the tumor necrosis factor receptor 
superfamily that is characterized by a cysteine-rich extracellular domain. Death 
receptors include Fas/Apo-l/CD95, TNF-Rl , DR3 (Apo-2), DR4 (tumor necrosis 
factor-related apoptosis-inducing ligand receptor 1 [TRAIL Rl]) , DR5 (TRAIL R2) 
and DR6 (Gupta, 2001; Locksley et al., 2001; Ozoren and El-Deiry, 2003). The death 
receptors also contain a homologous cytoplasmic sequence, death domain (DD). DD 
enables death receptors to signal a cascade of events that lead to apoptosis. 
When a death stimulus triggers the pathway, the ligands bind to their 
respective death receptors and the death domains attract the intracellular adaptor 
protein FADD (Fas-associated death domain), which, in turn, recruits the inactive 
preforms of caspases 8 and 10. The FADD protein and caspase 8 or 10 forms a 
death-inducing signaling complex (DISC) that leads to the activation of caspase 8 or 
10, the initiator caspases, which in turn activate the rest of the downstream caspases. 
In type II cells, caspase 8 interacts with the intrinsic apoptotic pathway by cleaving 
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Bid (a BH3 domain-only proapoptotic member of the Bcl-2 family), leading to the 
subsequent release of cytochrome c from mitochondria to amplify the apoptotic signal 
(MacFarlane, 2003; Strasser et al., 2000). 
Several other pathways and proteins regulate activation of the extrinsic 
pathway. Dysregulation of these modulators may lead to malignant transformation 
(Landowski et al., 1997). Regulators of the pathway include transcription factors, 
such as N F - K B and AP-1, that regulate the FasL gene, which is transcriptionally 
inactive (Wajant, 2002). Other inhibitors of the pathway include FAP-1, 
Fas-associated-death-domain-protein like interleukin-1 p-converting enzyme-like 
protease inhibitory proteins (FLIPs), and the soluble decoy receptors that antagonize 
the stimulation of death receptors by their ligands through competition (Krueger et aL, 
2001; Pan c"c//.’ 1997). 
Death receptors have been pursued as potential targets for cancer therapy for 
many years. TNF and FasL have extensive in vitro antitumor activity and have been 
utilized as potential therapeutic targets in vivo. However, they were also found to 
activate non-specific TNF receptors resulting in extensive ischemic and hemorrhagic 
lesions in several tissues leading to septic shock and fulminant hepatic failure in 
animal models (Havell et aL, 1988; Ogasawara et al., 1993). TRAIL has been 
introduced as an extrinsic pathway inducer that does not have the toxicity of FasL and 
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TNF (Ferreira et al., 2002). 
1.1.3.2 The intrinsic pathway 
The intrinsic apoptotic pathway is triggered by various extracellular and 
intracellular stresses, such as growth-factor withdrawal, hypoxia, DNA damage, and 
oncogene induction. Signals that are transduced in response to these stresses converge 
mainly onto mitochondria (Green and Reed, 1998). 
Mitochondrion is an organelle with two well-defined compartments: the 
matrix, surrounded by the inner mitochondrial membrane (IMM) and the 
intermembrane space, surrounded by the outer mitochondrial membrane (OMM). The 
IMM contains various molecules, including ATP synthase, electron transport chain, 
and adenine nucleotide translocator (ANT). Under physiological conditions, these 
molecules allow the respiratory chain to create an electrochemical gradient 
(membrane potential). IMM permeabilization leads to mitochondrial membrane 
depolarization. The intermembrane space contains cytochrome c, certain procaspases, 
adenylate kinase 2 and apoptosis-iiiducing factor (AIF). Permeabilization of the 
OMM, therefore, results in the release of these molecules (Green and Kroemer, 2004). 
Release of cytochrome c is one of the major steps in the mitochondrial 
pathway of apoptosis that is associated with changes in mitochondrial membrane 
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permeabilization (MMP) (Chipuk et al., 2006; Li et al, 1997). MMP is controlled by 
a variety of members of the Bcl-2 family (Kluck et al., 1997). Release of cytochrome 
c triggers the assembly of Apaf-1 (Apoptotic protease-activating factor) and 
procaspase 9 to form an apoptosome. ATP is required for the recruitment of 
procaspase 9 by Apaf-1 through CARD (caspase recruiting domain). Procaspase 9 is 
then autolytically cleaved to active caspase 9’ which then activates procaspase 3 to the 
active caspase resulting in cleavage of its substrates and apoptosis. Once cytochrome 
c is released, the downstream cascade of caspase activation is irreversible (Mohamad 
et al” 2005). 
1.1.3.3 The Bcl-2 family proteins 
One of the most important regulators of the intrinsic mitochondrial pathway is 
the Bcl-2 family proteins. The Bcl-2 family includes 17 or more members in 
mammalian cells, all of them share at least one conserved Bcl-2 homology (BH) 
domain. They function as a "life or death switch" that integrates diverse inter- and 
intracellular cues to determine whether or not the apoptosis pathway should be 
activated. The family can be divided into three subfamilies by their function and 
structure: the antiapoptotic subfamily (share all four BH domains (BHl-4)), the 
proapoptotic Bax-like family (with BHl-3 multidomains), and proapoptotic BH3-only 
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family (Gross et al., 1999; Hengartner, 2000). 
The antiapoptotic subfamily, including Bcl-2, BCI-XL, Bcl-w, Mcl-land A l , 
potently inhibits apoptosis in response to diverse cytotoxic conditions. They modulate 
cell death in part by affecting the translocation of cytochrome c and several other 
proteins (Kluck et al., 1997; Yang et al., 1997). Moreover, increased levels of 
antiapoptotic Bcl-2 family members can reduce activity of the proapoptotic Bcl-2 
family members, probably by sequestering them to sites where they cannot interact 
with the antiapoptotic Bcl-2 family members (Cheng e( al” 2001). Overexpression of 
Bcl-2 homologiies promotes neoplastic transformation by prolonging the lifespan of 
normally short-lived cells, thereby allowing them to accumulate additional oncogenic 
mutations (Coultas and Strasser, 2003). 
Members of the proapoptotic Bax-like subfamily (Bax, Bak and Bok) are 
very similar to Bcl-2 in sequence, particularly in three conserved BHl , 2 and 3 
domains. Both Bax and Bak have structures that closely resemble their antiapoptotic 
relatives but they promote rather than oppose apoptosis. In order to exert their effects, 
members of the Bax-like family must translocate from cytosol to insert to the OMM. 
During apoptosis, Bax, which is present in a monomer form, is translocated from 
cytosol to the mitochondrial membrane to form dimers or oligomers to facilitate the 
release of apoptogenic proteins, such as cytochrome c. Bak demonstrates similar 
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conformational changes in response to apoptotic stimuli. Bax and Bak lie downstream 
of BH-3 only proteins in the apoptotic pathway and their activation is a critical point 
of commitment to apoptosis. Deletion of both Bax and Bak will lead to severe 
impairment in apoptosis signaling (Chipuk et al., 2006; Esposti and Dive, 2003; Zong 
c" a/., 2001). 
The proapoptotic BH-3 only family includes at least eight members: Bik, Bad, 
Bid, Bim, Bmf, Hrk, Noxa and Puma. These proteins are largely unrelated in 
sequence to either Bcl-2 or each other, apart from the signature BH3 domain, which is 
essential for their killing function. They are required for initiation of apoptosis 
whereas the Bax-like proteins act further downstream in the signaling pathway. 
Mutations in BH3-only proteins or their regulators may be pathogenic. Following a 
death signal, BH3-only proteins undergo post-translational modifications, like 
dephosphorylation and cleavage. Such modifications result in their activation and 
translocation to OMM, where they interact with the Bax-like proteins, leading to their 
oligomerization to release apoptogenic factors from mitochondria. In addition, they 
may also initiate apoptosis by binding to antiapoptotic proteins thereby changing their 
conformation into a state that together with oligomerized Bax/Bak to promote the 
release of caspase adaptors (Gross et al,, 1999; Huang and Strasser, 2000; Strasser et 
al., 2000). 
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Bin! associates with microtubule complexes. In response to an apoptotic 
stimulus, Bim dissociates and translocates to O M M and therefore apoptosis proceeds 
(Puthalakath et al., 1999). In the presence of survival factors, Bad is phosphorylated 
and is sequestrated in the cytoplasm by interacting with 14-3-3 protein which 
dissociated from Bcl-2 and BC1-XL to promote cell survival. Conversely, in the 
absence of survival factors, Bad is dephosphorylated. Its BH3 domain binds to and 
inactivates Bcl-2 or BC1-XL at OMM, thereby promoting apoptosis (Zha et al., 1996). 
Active caspase 8 from the death receptor pathway can cleave Bid so that the truncated 
Bid translocates from the cytosol to OMM and enhances the Bax-mediated 
cytochrome c release. Bid provides a mechanism by which the death receptor pathway 
is linked to the mitochondrial pathway (Li et al., 1998). 
1.1.3.4 Execution of apoptosis 
Execution of the death signals is mediated through activation of the effector 
caspases. The intrinsic and extrinsic apoptotic pathways converge to caspases 3，6 and 
7 which cleave a number of different substrates, contributing to morphological and 
biochemical alterations and characteristics of apoptosis. The downstream caspases 
induce cleavage of cytoplasmic proteins, including actin and gelsolin, nuclear proteins 
such as lamin A, proteins involved in DNA metabolism and repair such as PARP, 
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protein kinases, proteins involved in signal transduction pathways and proteins 
involved in regulation of cell cycle and proliferation (Earnshaw el al.’ 1999; 
Thornberry and Lazebnik, 1998). One of the substrates, PARP (poly(ADP-ribose) 
polymerase), has been frequently used as an indicator of apoptosis. It is a nuclear 
enzyme that is activated by DNA strand breakage. Once activated, it is actively 
involved in DNA repair. At physiological conditions, PARP plays an important role in 
maintaining genomic stability, controlling homologous recombination, and regulating 
centrosome function. On the other hand, caspase 3 activation during apoptosis causes 
the cleavage and inactivation of PARP (Hassa et al, 2006; Kaufmann et al., 1993; 
Lazebnik et al.’ 1994). Through cleavage of 40 or more substrates, caspases cut off 
the cell contacts with the surrounding cells, reorganize the cytoskeleton, shut down 
DNA replication and repair, interrupt splicing, destroy DNA, disrupt the nuclear 
structure, induce the cell to display signals that mark it for phagocytosis, and 
disintegrate the cell into apoptotic bodies. 
Caspases play an important role in apoptosis execution but at the same time 
there are a variety of inhibitors regulating the proteolytic systems which control the 
cell-death proteases. One of the inhibitor families, the family of lAP (inhibitors of 
apoptosis) proteins, has been found to inhibit apoptosis through caspases inhibition, 
which includes XIAP, cIAPl , cIAP2, NAIP, MLIAP, ILP2, livin, apollon and 
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survivin. All of these proteins possess at least one domain known as the baculoviral 
lAP repeat, which is essential for their antiapoptotic function. lAPs directly bind to 
and inhibit caspase 3, 7 and 9. Some members of the lAP proteins are expressed in 
certain human cancers. Removal of their inhibitory effects seems to be potentially 
useful in sensitizing the cancer cells to anticancer drugs (Salveseii and Duckett, 2002). 
1.1.4 Melanoma 
Melanoma is the most aggressive form of skin cancer which develops through 
the malignant transformation of melanocytes, the pigment-forming cells of the skin. 
There are about 133,000 new cases of melanoma worldwide each year. At the present 
time, only a small proportion of people (< 5 %) with metastatic melanoma live more 
than two years (Kleihues et al.’ 2003). The mainstay for the treatment of systemic 
metastases is chemotherapy. Regimes using dacarbazine are the most commonly 
applied therapy for metastatic melanoma. However, only a minority of patients 
obtains long-lasting responses, and the long-term survival benefit derived from this 
drug is extremely limited (Middletoii et al., 2000). Although new therapies have 
become available, unfortunately none have been proven better than traditional 
chemotherapy in a majority of patients. There is still no highly effective single agent 
or combination being developed and metastatic melanoma is characterized by drug 
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resistance. The basis for drug resistance in melanoma includes drug transport, 
detoxification, enhanced DNA repair, and dysregulation of apoptosis (Grossman and 
Altieri, 2001; Satyamoorthy et al.’ 2001; Soengas and Lowe, 2003). 
As mentioned previously, most chemotherapeutic drugs ultimately act through 
induction of apoptosis. Reduced efficacy of chemotherapeutic drugs in melanoma is 
likely related to the relative inability to induce apoptosis in melanoma cells. 
Impairment of the proapoptotic pathway or loss/inactivation of a proapoptotic factor 
may lead to apoptosis resistance, such as the defect in death receptor signaling 
pathway through down-regulation of the death receptor levels (Zhuang et al., 2006). 
Alternatively, over-expression of apoptotic inhibitors may account for increased 
apoptosis resistance in melanoma cells, such as the over-expression of antiapoptotic 
Bcl-2 family proteins (Leiter et aL, 2000)，FLIPs (Irmler et al., 1997) and lAP family 
proteins (Grossman et al., 1999; Takeuchi et al., 2005). 
Dysregulation of apoptosis constitutes one of the key factors responsible for 
acquired drug resistance in melanoma. Identifying the molecular aspects of apoptosis 
resistance in melanoma offers new potential therapeutic targets to improve the current 
treatment. 
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1.2 Polyunsaturated fatty acids (PUFAs) 
1.2.1 Chemistry, classification, metabolic conversion and sources 
All fatty acids have a hydrocarbon (CH!) chain with a carboxyl group 
( H 0 - C = 0 ) at one end and a methyl group (CH3) at the other end. The hydrocarbon 
chain of each fatty acid varies in length from 4 to 22 or more carbons, and those with 
more than 20 carbons are referred to as long chain fatty acids. Fatty acids with two or 
more carboii-to-carbon double bonds in the hydrocarbon chain are referred to as 
polyunsaturated fatty acids (PUFAs). There are at least four independent families of 
PUFAs, depending on the parent fatty acid from which they are synthesized. They 
include: the "co-3" series derived from a-linolenic acid (ALA, 18:3co3); the "co-6" 
series derived from cw-linoleic acid (LA, 18:2co6); the "co-9" series derived from oleic 
acid (OA, 18:10)9); and the "co-7" series derived from palmitoleic acid (PA, 16:lco7). 
The notation "co-x" is used to describe the position of double bond nearest to the 
methyl group of the fatty acid; for instance, co-3 fatty acids have the first double bond 
at the third carbon atom from the methyl terminal of the hydrocarbon chain. 
OA (co-9) can be synthesized by all mammals, including humans. However, 
both ALA ((0-3) and LA (co-6) cannot be synthesized by mammals and they must be 
obtained from diet, thus they are considered as "essential fatty acids". Algae, fungi, 
bacteria, insects and some other invertebrates possess the array of desaturase and 
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elongase activities required for the de novo production of the co-3 and co-6 fatty acids, 
thus they are the primary producers of these compounds in nature. Mammals rely on 
microbial and plant sources for their provision. In human, both ALA and LA are 
metabolized to longer-chain fatty acids by various cycles of desaturation and 
elongation, largely in the liver. ALA is converted to eicosapentaeiioic acid (EPA, 
20:5CL)3), and thence to docosahexaenoic acid (DHA, 22:6co3), LA, on the other hand, 
is the metabolic precursor of y-linolenic acid (GLA, 18:3co6), dihomo-y-linolenic acid 
(DGLA, 20:3(o6) and arachidonic acid (AA, 20:4co6) (Fig. 1.3). These two classes of 
fatty acids are not inter-convertible although they share the same enzymes in their 
metabolic pathways, and they often have important opposing physiological functions 
(Gill and Valivety, 1997; Rose and Connolly, 1999). 
The main dietary sources of LA are cereals, eggs, poultry, most vegetable oils, 
corn oil, sunflower oil and margarine. The main dietary sources that ALA can be 
obtained are canola oil, flaxseed oil, linseed oil, rapeseed oil, walnuts and green leafy 
vegetables. The major dietary source of EPA and DHA is marine fish (Das, 2006). 
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Fig. 1.3 The Metabolic Pathways of the Essential Fatty Acids LA and ALA 
Dietary LA is converted to DGLA and AA while ALA is converted to EPA 
and DHA. Each metabolic sequence competes for the same enzyme systems, 
with the affinity for co-3 being greater than co-6 fatty acid. 
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1.2.2 Epidemiology studies 
Epidemiological evidence has established that co-3 PUFAs which are abundant 
in fish oils, have profound effects on many human disorders and diseases, including 
cardiovascular disease and cancer. The first clue that co-3 PUFAs may exert beneficial 
effects on human health has come from epidemiology studies on populations in which 
fish is a major component of the diet. Dyerberg et al (1975) observed that Greenland 
Eskimos, who consumed diet rich in co-3 PUFAs, had a low rate of cardiovascular 
disease. Later, many studies have shown an inverse association between fish oil 
consumption and the risk of coronary heart disease or sudden cardiac death in the 
general population (Daviglus et al., 1997; Kris-Etherton et al., 2002; Ratnesar et cd., 
2000). 
Ill addition to the beneficial cardiovascular effects, fish oil was also reported 
to have anticancer properties. An epidemiology study of South West Coast fisherman 
on South Africa showed that despite smoking, high sodium intake, low consumption 
of fiber, fruits and vegetables, absence of vitamin supplementation and low levels of 
dietary micronutrients, the fisherman had a lower incidence of colorectal cancer 
compared to the urban whites. This was believed to be attributed to the protective 
effects of fish oil in their diets (Schloss et al., 1997). Furthermore, cross-national and 
case-controlled studies have shown an inverse relationship between fish consumption 
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and incidence and mortality rate of prostate (Hebert el al., 1998; Kobayashi et al., 
1999) and breast cancer (Gago-Dominguez et al., 2003; Hursting et al., 1990). The 
beneficial effects of fish oils are mostly attributed to their content of the co-3 PUFAs, 
EPA and DHA. 
However, not all PUFAs display the same effect. Omega-6 fatty acids are 
generally considered "bad" for human health. The increased intake of co-6 PUFAs, 
which are rich in Western diet, leads to the increased production of thromboxane A2, 
leukotriene B4, IL-lp, IL-6, TNF and GRP. Increased production of these factors is 
believed to be associated with cardiovascular diseases, diabetes, cancer, obesity, 
autoimmune diseases and depression. Therefore, the balance between co-6 and co-3 
PUFAs is very important for homeostatsis and normal development (Simopoulos, 
2006). 
1.2.3 Docosahexaenoic acid (DHA) 
1.2.3.1 Sources 
Human can easily obtain ALA, the precursor of DHA, from their diet. 
However, the endogenous conversion of ALA to DHA is limited and inefficient. Fish 
or marine organisms offer good sources of DHA. However, some species of fish may 
contain significant levels of methylmercury, polyclilorinated biphenyls (PCBs)， 
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dioxins, and other environmental contaminants. Also, fish oils contain a complex 
mixture of PUFAs of varying qualities and quantities. Therefore, fish may not be the 
best choice for the source of DHA (Brunner, 2006). In fact, fish do not produce DHA. 
It is produced by single celled marine organisms that fish and shellfish regularly 
consume in their diets. Therefore, the single celled marine organisms, such as 
microalgae, provide an alternative source of DHA. Their oils are believed to be a 
cleaner and more concentrated source of DHA than fish oils (Cohen et al； 1995). 
1.2.3.2 DHA and cancer 
Soon after the original epidemiology studies on fish oil diets became 
appreciated, DHA has been under intense investigation for its effect on various 
diseases. DHA has been reported to have positive effect on an enormous variety of 
human afflictions (Horrocks & Yeo, 1999). Extensive researches have been carried 
out to study the effect of DHA on cancer cells. DHA has been shown to exhibit 
significant growth inhibitory and cytotoxic effects on certain human cancers, 
involving colon cancer (Calviello et al.., 2004; Chen and Istfan, 2000; Hofmanova et 
al, 2005; Narayanan et al, 2001; Narayanan et ai., 2003; Narayanan et al., 2004), 
breast cancer (Chiu et ciL, 2004a; Schley et al., 2005), prostate cancer (Chung et al., 
2001； Narayanan et al., 2005), leukemia (Siddiqui et al., 2003; Siddiqui et al., 2001; 
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Sturlan et al., 2003) and liver cancer (Calviello et al., 1998). DHA has also been 
found to induce cell cycle arrestment and apoptosis by various mechanisms that affect 
eicosanoid production, formation of potent lipid peroxidation, activity of specific 
enzymes, transcription events, and membrane structure and functions (Stillwell et al., 
2005). 
DHA exerts its anticancer effect by slowing down the growth of cancer cells 
via inhibition of cell cycle progression (Albino et al., 2000; Chen and Istfan, 2001; 
Chiu et al” 2004b; Siddiqui et al., 2003). A possible role for DHA in cell cycle 
modulation can be accounted by a comprehensive study of Siddiqui et al, using 
Jurkat leukemic cells as the model (Siddiqui et al., 2003), They demonstrated that low 
doses of DHA induced S phase cell cycle arrest in the leukemic cells through 
hypophosphorylation of pRb by stimulating protein phosphatase and inhibiting cdk2 
kinase activities. DHA increased ceramide formation, probably due to the induced 
activation of sphingomyelinase in the plasma membranes. The ceramide then 
mediated the cell cycle arrest via activation of ceramide-activated protein 
phosphatases (CAPP). The activated CAPP (protein phosphatase 1 and/or 2A) then 
dephosphorylated the phosphorylated pRb. Beside, ceramide also caused increased 
expression of p21, and subsequently, inhibition of cyclin A/cdk2 activity. 
DHA induces apoptosis in cancer cells, whereas it protects neuronal, retinal, 
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and cardiac cells against apoptosis (Kim et al., 2000; Nair et a I., 1997; Rotstein ct al., 
1997). In addition to cell cycle arrestment, the DHA-induced ceraniide formation may 
also involve in the induced apoptosis in various cell lines, including breast (Wu et al., 
2005) and leukemic (Siddiqui et al., 2001) cells. Activation of protein phosphatase by 
ceramide mediates the release of cytochrome c and activation of caspases via 
dephosphorylation of Bcl-2 proteins leading to apoptosis. 
Besides inducing ceramide formation, DHA comprises a number of 
unsaturated bonds that can be readily oxidized to generate oxidative stress inside the 
cells. The reactive oxygen species (ROS) and lipid peroxidation products generated 
during DHA metabolism might cause damages and kill the cancer cells as they are 
usually defective in the anti-oxidative systems while normal cells are not 
(Baumgartner et al., 2004; Chen and Istfaii, 2000; Hofmaiiova et al., 2005; Sturlan et 
al., 2003). Increased cellular ROS by DHA can lead to collapse of the mitochondrial 
membrane potential, release of cytochrome c, activation of the caspase cascade, and 
finally, apoptosis. In addition, lipid peroxidation may enhance the expression of Fas 
and suppress Bcl-2 expression (Das, 1999). 
In addition to inducing cytotoxicity in tumor cells, DHA also showed potent 
inhibitory effects on chemical-induced carcinogenesis. An in vitro study demonstrated 
that DHA inhibited Epstein-Barr virus early antigen (EBV-EA) activation induced by 
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the tumor promoter TPA (12-0-tetradecanoylphorbol-13-acetate) in Raji cells without 
killing the cells (Akihisa et al., 2004). Furthermore, an in vivo experiment using a rat 
multi-organ carcinogenesis model showed that DHA significantly reduced the 
induction of tumors in the large intestine and with a similar tendency to reduce the 
tumor formation in small intestine and lung (Toriyama-Baba et al., 2001). 
32 
1.3 Objectives 
(1) To investigate the in vitro growth inhibitory effect of DHA from microalga 
Cryplhecodinium cohnii on human melanoma A375 cells. 
(2) To determine the cellular and molecular mechanisms by which the microalgal 
DHA generates its growth inhibitory effect on the melanoma cells. 
(3) To study the in vivo anticancer potency of the microalgal DHA using A375 
xenograft in athymic mice. 
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Chapter 2 Materials and Methods 
2.1 III vitro studies of DHA on growth and survival of human cancer cells 
2.1.1 Cell cultures 
In this study, human cancer cell lines including melanoma A375, colorectal 
adenocarcinoma Caco-2, hepatocellular carcinoma HepG2, breast carcinoma MCF-7 
and prostate carcinoma PC-3 were used to study the cytotoxic and cytostatic effects of 
DHA. All cell lines were obtained from American Type Culture Collection (Rockville, 
MD). A375 and Caco-2 cells were maintained in Dulbecco's modified Eagle's 
medium (DMEM) (Gibco, Rockville, MD); HepG2 and MCF-7 cells were maintained 
in RPMI-1640 medium (Sigma, St. Louis, MO); while PC-3 cells were maintained in 
F12K medium (Gibco). All media were supplemented with 0.2 % sodium bicarbonate 
(Sigma), 10 % heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 
|j.g/ml streptomycin and 0.25 |a.g/ml amphotericin B (all from Gibco). All cell lines 
were kept under a fully humidified atmosphere with 5 % CO2 at 37 °C in 25 cm^ 
sterile polystyrene tissue culture flasks. All cultures were passaged three times a week. 
Upon passages, the cells were detached from the flasks by treating with 
Trypsin-EDTA solution (containing 0.25 % trypsin and 0.02 % EDTA in PBS) for 1-2 
mill, and the reaction was then stopped by the corresponding medium. An appropriate 
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aliquot of the cell suspension was added to a new culture vessel. Cells were generally 
seeded at a density of 1 x lO^ viable cells/cm^. The number of viable cells was 
counted under a hemocytometer after staining with 0.4 % trypan blue solution 
(Sigma). 
2.1.2 Studies of growth inhibition of DHA on human cancer cells 
Docosahexaenoic acid (DHA), from microalga Ciypthecodmium cohnii 
(purity 98.6 %), used in this study was purchased from Martek Biosciences, Columbia, 
MD. DHA stock solution was mixed with 1 % bovine serum albumin (BSA) 
immediately before use, and serial dilutions were performed with cell culture medium 
just before each experiment. Different cancer cells were seeded in 96-well flat-bottom 
microliter plate at 2 x 10^ viable cells/well/100 \ i l They were allowed to grow for 24 
h for acclimatization. The cells were then incubated with 0, 20, 40, 80, 160, 320 or 
640 jaM DHA for 72 h (Chiu et ciL, 2005). Different assays were then performed to 
examine the effects of DHA on cancer cell growth. 
2.1.2.1 MTT assay 
The cytotoxic and cytostatic effects of DHA on A375, Caco-2, HepG2, 
MCF-7 and PC-3 cells were determined by MTT assay. MTT solution was 
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freshly prepared by dissolving MTT (3-(4,5,-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) (Sigma) in filtered PBS at 5 mg/ml. At the end 
of 72 h DHA treatment, 10 of the MTT solution was added to each well, 
and the plate was incubated at 37 °C for 5 h. After incubation, the medium was 
removed and the blue formazan formed was dissolved in 150 of 0.04 N 
HCl-isopropanol. All the wells were mixed by pipetting up and down until the 
crystals were dissolved completely. Optical density of the blue formazan 
solution in each well was determined at 570 iim by a microplate reader 
(Mosmann, 1983). All tested concentrations were done in triplicate wells. 
Percentage of growth inhibition of the cancer cells was calculated by the 
following equation, and the concentration-growth inhibition curve was plotted. 
Growth inhibition = 
Average absorbaiice of treatment group 
(
1- 、 X 100% 
Average absorbance of control group , 
2.1,2.2 Chemiluminescent-bromodeoxyuridine (Chemi-BrdU) immunoassay 
Effect of DHA on the proliferation of A375 cells was further studied using 
the Cell Proliferation ELISA, BrdU (Chemiluminescence) Kit (Roche 
Molecular Biochemicals, Mannheim, Germany). After DHA treatment, 10 \x\ 
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BrdU labeling solution (provided) was added to each well and incubated at 37 
� C for 2 h. After centrifugation at 300 g for 10 miii, the supernatant was 
removed, and the plate was aspirated for 15 min. 200 \i\ of Fix-Denat solution 
(provided) was added to each well to fix the cells, and the plate was allowed to 
stand for 30 min at room temperature. After removing the Fix-Denat solution, 
100 )Lil of the diluted anti-BrdU-POD working solution (provided) was added 
to each well, and incubated for 90 min at room temperature. After rinsing the 
wells with the washing buffer (provided) for three times, 100 \x\ substrate 
solution was added and allowed to react for 3 min with shaking at room 
temperature. The luminescence emitted from the wells was determined with a 
microplate luminometer with photomultiplier technology. Percentage of 
inhibition on the cell proliferation was calculated by the following equation, 
and the concentration-proliferation inhibition curve was plotted. 
Cell proliferation inhibition = 
Average luminescence of treatment group 
( 1 - ^ x 100% 
\ Average luminescence of control group , 
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2.1.3 Studies of growth inhibitory mechanism of DHA onA375 cells 
Melanoma A375 cells were seeded in 25 cm^ sterile polystyrene tissue culture 
flasks at density 4 x 10^ cells/cm^. After 24 h of incubation for acclimatization, the 
cells were incubated with 0, 40, 80 or 160 \iM DHA for 24, 48 or 72 h. After 
treatment, about 2 x 10^ cells were harvested, and were then subjected to different 
analyses. 
2.1.3.1 DNA-flow cytometry analysis 
Effects of DHA on cell cycle distribution and apoptosis induction in the 
melanoma cells were analyzed by Epics XL-MCL flow cytometer (Beckman 
Coulter, Miami, FL). Cells harvested from 24, 48 and 72 h of DHA treatment 
were washed twice with PBS and centrifuged at 514 g for 5 min. The cells 
were then fixed in 70 % ethanol at - 2 0 � C overnight. The fixed cells were 
washed twice with PBS, and then incubated in dark for 30 min with 1 ml PBS 
solution, containing 1 mg/ml riboniiclease and 10 j^g/ml propidium iodide (PI) 
(Sigma). The red fluorescence of DNA-bound PI in individual cells was 
measured at > 625 iim by the flow cytometer. Cell cycle distribution, i.e. 
proportion of cells in different phases of cell cycle, was analyzed using 
Multicycle software (Phoenix Flow Systems, San Diego, CA). Cells 
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displaying hypodiploid DNA content were also quantified and they were 
regarded as the apoptotic population (Darzynkiewicz et aL, 1997; Vermes et 
al., 2000). 
2.1.3.2 Western blot analysis 
Effects of DHA on expressions of some apoptosis-related protein in A375 
cells were studied semi-quantitatively by Western blot analysis. 
a) Protein extraction 
To prepare whole cell lysate, the cells were harvested after treating 
with 0, 40，80 or 160 i^M DHA for 72 h by washing twice with PBS and 
centrifugation at 514 g for 5 miii at 4 °C. The cell pellet was then 
resuspended in 49 \i\ lysis buffer (20 mM Tris-HCl at pH 8.0, 150 mM 
NaCl, 5 niM EDTA, 0.2 % BSA, 1 % Triton X-100) supplemented with 1 
|il protease inhibitor cocktail (BD Biosciences, San Jose, CA) for 45 min 
on ice. After that, the lysate was centrifuged at 15 000 g for 15 min at 4 � C . 
The supernatant was used immediately or stored at -20 °C. 
b) Determination of protein concentration 
Protein concentration of the cell lysate was determined by the standard 
bicinchoninic acid assay (BCA) kit (Pierce，Rockford, IL). One microliter 
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from each sample was diluted with 49 f^l ultrapure water for protein 
content measurement. A standard curve was prepared using 50 |al of 0, 25, 
50, 100, 200 and 400 |ag/ml of BSA solution. One milliliter of BCA 
working reagent, containing 50 parts of reagent A and 1 part of reagent B 
(provided), was then added to each tube and incubated for 30 min at 37 °C. 
After incubation, all the tubes were cooled to room temperature. 
Absorbance was measured at 562 nm using BioPhotometer (Eppendorf, 
Hamburg, Germany). Protein concentrations of the samples were 
determined from the standard curve. 
c) Protein denaturation 
After protein quantification, equal amount of proteins from the control 
and treatment groups was mixed with loading buffer (1:1) (0.5 M Tris-HCl 
at pH 6.8, 25 % glycerol, 2 % SDS, 0.01 % bromophenol blue and 5 % 
2-mercaptoethanol), and then denatured at 95 °C for 5 min. 
d) SDS-PAGE and immunodetection 
Twenty to one hundred micrograms of proteins were resolved on 13 % 
sodium docecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
minigel, followed by electrophoretic transfer to nitrocellulose membranes 
(Hybond ECL; Amersham, Buckinghamshire, UK). The membrane was 
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then blocked for 1 h in blocking buffer (Tris-buffered saline with 0.1 % 
Tween-20 containing 5 % non-fat dry milk). Immunodetection was 
performed by overnight incubation with the primary antibody diluted in 
the blocking buffer at 4 °C with gentle shaking. 
Primary antibodies specific to PARP, caspase-3, caspase-6, caspase-7, 
caspase-8, caspase-9，caspase-10, BC1-XL, Bak, Bad, Bid, Bim were 
obtained from Cell Signaling Technology, Beverly, MA; antibodies 
specific to Bcl-2, Mcl-l，Bax, DR4 and TRAIL were purchased from BD 
Biosciences; the antibody specific to p-actin was obtained from Sigma. 
Primary antibodies were used at 1:250 to 1:5000 dilutions. 
After 5 min washing in washing buffer (Tris-buffered saline with 0.1 % 
Tween-20) for 3 times, the blot was probed with horseradish peroxidase 
(HRP)-conjugated secondary antibodies (Cell Signaling Technology) in 
blocking buffer at 1:2000 dilution for 1 h at room temperature. The 
membrane was washed again (3 times each for 5 min), and the proteins 
were visualized by incubation with a chemiluminescent substrate (Cell 
Signaling Technology) and exposure to X-ray film, 
e) Densitometric analysis 
Densitometric measurement of imniunoblots was performed using 
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LumiAnalyst 3.1 software (Roche Molecular Biochemicals). 
2. J.3.3 Caspase inhibitor studies 
To investigate the role of caspases in DHA-induced apoptosis, A375 cells 
were seeded in 25 cm^ tissue culture flasks at density of 4 x 10^ cells/cm^. 
After 24 h of acclimatization, the cells were incubated with 40 |aM caspase 
inhibitor (dissolved in DMSO) for 1 h, followed by 72 h of 160 \xM DHA 
treatment. Some cells were also treated with BSA and DMSO only as vehicle 
control. The caspase inhibitors used were general caspase inhibitor 
(Z-VAD-FMK), caspase-3 inhibitor (Ac-DEVD-CHO, Z-DEVD-FMK), 
caspase-8 inhibitor (Ac-IETD-CHO) and caspase-9 inhibitor (Z-LEHD-FMK) 
(all from PharMingen, San Diego, CA). After treatment, the cells were 
analyzed by Western blotting for PARP cleavage as indicator of apoptosis 
(detailed in Section 2.1.3.2). 
2.1.3.4 Mitochondrial membrane potential analysis 
Loss of mitochondrial membrane potential was detected by using 
the potential-sensitive fluorescent probe, tetramethylrhodamine ethyl ester 
(TMRE) (Molecular Probes, Eugene, OR). A375 cells treated with DHA for 72 
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h were harvested and incubated with 25 nM TMRE for 15 min at 37 °C prior 
to analysis on the flow cytometer. As a positive control, some cells were 
incubated with 100 |iM potential-disrupting agent, carbonyl cyanide 
3-chlorophenyIhydrazone (CCCP) (Sigma) for 24 h. Data are displayed as the 
percentage of cells with reduction in mitochondrial membrane potential 
(Essmann et al., 2004). 
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2.2 In vivo study of the anticancer effect of DHA on A375 cells 
2 2.1 Animals 
All experimental procedures using laboratory animals were approved by the 
Animal Experimental Ethics Committee of The Chinese University of Hong Kong. 
Male athymic Balb/c nude mice (6-7 weeks old) were obtained from the Laboratory 
Animal Service Centre (LASEC) of CUHK. The animals were housed in sterile 
rodent microisolator cages in Room 403 of LASEC, under clean and controlled room 
conditions at 21 ± 2 with an alternating 12 h light and dark cycle. The animals 
were freely accessible to sterile water and rodent chow. All the mice were allowed to 
acclimate in the laboratory for one week before the start of each experiment. 
2.2.2 Cell inoculation and treatments 
The human melanoma A375 cell line was maintained in vitro, and was 
passaged three times a week (detailed in Section 2.1.1). Viable cells were counted by 
hemocytometer and trypan blue exclusion method. Cell suspension with a density of 
2.5 X 10^ viable cells/ml in DMEM was prepared for inoculation. 
Five million A375 cells (i.e. 0.2 ml of the cell suspension) were inoculated 
subcutaneoLisly onto the back of each athymic nude mouse. Ten days after inoculation, 
the tumor-bearing mice were randomly divided into 4 groups, each containing 6 mice. 
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Mice of the three treatment groups were administered with 12.5, 50 or 200 mg/kg 
body weight DHA by oral gavage daily for 10 consecutive days. Mice in the control 
group were administered with ultrapure water only. Twenty-six days after inoculation, 
the mice were sacrificed by cervical dislocation. The tumors were enucleated and 
weighed. Proteins were also extracted from the tumors for further investigations. 
2.2.3 Western blot analysis 
Tumor proteins from the control and 50 mg/kg DHA treatment groups were 
extracted and subjected to Western blot analysis following the procedures described in 
Section 2.1.3.2. 
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2.3 Statistical analysis 
Results are expressed as mean 土 standard deviation (S.D.). Difference in means 
between the control and treatment groups was compared by Student's Mest;年p < 0.05, 
**p < 0.01, and *** p < 0.001. 
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Chapter 3 Results 
3.1 In vitro studies of DHA on growth and survival of human cancer cells 
3.1.1 DHA reduced proliferation and survival of human cancer cells 
MTT assay was firstly applied to study the effects of DHA on proliferation and 
survival of A375, Caco-2, HepG2, MCF-7 and PC-3 cells. DHA reduced proliferation 
and survival of the cancer cells in a dose-dependent manner. At the highest 
concentration of 640 [iM after 72 h of incubation, DHA reduced proliferation and 
survival of A375, Caco-2, HepG2, MCF-7 and PC-3 cells by 92.78 %, 89.05 %, 85.81 
%, 80.28 % and 73.37 % respectively, when compared to their control levels. The 
inhibition on A375 cells reached a plateau at 320 jiM DHA treatment (Fig. 3.1, Table 
3.1). Of all the cancer cell lines of different liistotypes tested in this study, human 
melanoma A375 was found to be the most responsive one to the inhibition of DHA. 
To further investigate the cytostatic effect of DHA on the melanoma cells, 
* level of BrdU incorporation was used to indicate the extent of cell proliferation under 
the influence of DHA. As BrdU is an analogue of pyrimidine, which incorporates into 
the DNA of proliferating cells, level of BrdU incorporation represents the proliferative 
potential of the cancer cells. As shown in Fig. 3.2, after 72 h of incubation with 
increasing concentrations of DHA from 80 to 320 ^M, a dose-dependent decrease (up 
47 
to 81.5 % compared to the control level) in the incorporation of BrdU, i.e. the 
proliferative potential of the melanoma cells, was observed. Therefore, both MTT and 
BrdU studies illustrated that DHA inhibited growth of A375 cells dose-dependently 
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Fig. 3.2 Effect of DHA on the Proliferation ofA375 Cells 
The cells were incubated with 0, 80, 160 and 320 |LIM of DHA respectively 
for 72 h and then measured by chemi-BrdU assay. Results are expressed as 
mean 土 S.D. (n=3). Difference in means between the control and treatment 
groups was compared by Student's "test，*p < 0.05; **p < 0.01; and ***p < 
0.001. 
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3.1.2 DHA modulated cell cycle of A375 cells 
By comparing the proportion of cells in the different phases of cell cycle, 
effect of DHA on cell cycle progression in the melanoma cells was elucidated. The 
cancer cells were treated with 40, 80 and 160 DHA for 72 h, and were then 
subjected to flow cytometric analysis of DNA content. DHA accumulated the G2/M 
cells and S cells from 17.2 % and 30.9 % in control cells to 25.5 % and 33.3 % in 160 
|aM DHA treated cells, respectively. The Gq/Gi cells concomitantly reduced from 51.8 
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Fig. 3.4 Numeric Data Showing the Effect of DHA on Cell Cycle ofA375 Cells 
The cells were incubated with 0, 40, 80, 160 f^M DHA for 72 h, and were 
then subjected to flow cytometric analysis of DNA content using PI staining. 
Results are expressed as mean 土 S.D. (n=3). Difference in means between 
the control and treatment groups was compared by Student's /-test, < 0.05; 
and < 0.01. DHA arrested cells in G2/M and S phase with reduction of 
Go/Gi cells. 
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3.1.3 DHA induced apoptosis in A375 cells 
Effect of DHA on cancer cell apoptosis, an important cancer therapeutic 
strategy, was also investigated. According to the results from DNA-flow cytometry 
(Fig. 3.3), DHA induced DNA fragmentation, which is a characteristic feature of 
apoptosis, in the melanoma cells. About 20 % of apoptosis was induced by 160 |iM 
DHA (Fig. 3.5) while the induction of apoptosis occurred in a time dependent manner 
(Fig. 3.6). 
Induction of apoptosis in the melanoma cells by DHA was further investigated 
by Western blot study. Cell lysates from the melanoma cells were immiinoblotted with 
a specific antibody that recognizes full-length PARP (116 kDa) and its cleaved form 
(89 kDa). PARP is an enzyme that involves in DNA repair and genomic maintenance. 
Its cleavage indicates the occurrence of apoptosis, and also suggests the activation of 
proteolytic caspases in the cell death process. During the execution phase of apoptotic 
cell death, proteolysis of the intact form of PARP results in the loss of normal PARP 
function, which facilitates cellular disassembly. 
After 72 h incubation with 160 jiM DHA, PARP cleavage was observed in the 
treated cells, in comparison to the intact PARP in the control cells (Fig. 3.7). Results 
from the immunoblot suggest that DHA induces apoptosis in the melanoma cells 
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Fig. 3.5 Numeric Data Showing the Effect of DHA on Apoptosis Induction in 
A375 Cells 
The cells were incubated with 0, 40，80, 160 |iM DHA for 72 h, and were 
then subjected to flow cytometric analysis of DNA content using PI staining. 
Cells with hypodiploid DNA content were counted, and their numbers are 
expressed as a percentage of total population. Results are expressed as mean 
土 S.D. (n=3). Difference in means between the control and treatment groups 
was compared by Student's ,-test, **p < 0.01. 160 jaM DHA induced 
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Fig. 3.6 Numeric Data Showing the Apoptotic Effect of DHA on A375 Cells at 
Different Treatment Time 
The cells were incubated in the absence or presence of 160 |aM DHA for 24, 
48 and 72 h, respectively and were then measured by flow cytometry using 
PI staining. Cells with hypodiploid DNA content were counted, and their 
numbers are expressed as a percentage of total population. Results are 
expressed as mean 土 S.D. (n=3). Difference in means between the control 
and treatment groups was compared by Student's /-test, < 0.05; and 
< 0.01. 160 |aM DHA induced apoptotic cells with fragmented DNA in a 
time dependent manner. 
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Fig. 3.7 Representative Immunoblot Showing the Effect of DHA on PARP 
Protein in A375 Cells 
Lysates from melanoma cells treated with 0，40, 80 or 160 pM DHA for 72 h 
were analyzed by Western blotting using a specific antibody. The result of a 
representative experiment is shown here. DHA at 160 ^iM induced PARP 
cleavage in the melanoma cells, suggesting that the apoptosis might be 
induced via activation of caspases. p-actin was included as loading control to 
normalize expressions of the PARP protein. 
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3.1.4 Caspase activations were involved in the DHA-induced apoptosis in A375 
cells 
As mentioned in Section 3.1.3, DHA-induced apoptosis of A375 cells was 
associated with cleavage of PARP, implying the possible involvement of caspases in 
the cell death mechanisms since PARP is one of the substrates of caspase 3 (Gross et 
al., 1999). General caspase inhibitor was used to further evaluate whether the 
DHA-induced apoptosis in the melanoma cells is caspase dependent or not. 
A375 cells were treated with general caspase inhibitor for 1 h prior to 72 h 
DHA incubation. Lysates from treated melanoma cells were immunoblotted with a 
specific antibody against PARP. Inhibition of caspase activities in A375 cells 
subsequently inhibited DHA-induced PARP cleavage (Fig. 3.8). 
Fig 3.9 shows the DNA histogram of treated A375 cells analyzed by flow 
cytometry after general caspase inhibitor and DHA treatment. Results show that 
apoptosis in the DHA treated A375 cells was significantly blocked by pre-incubation 
with general caspase inhibitor by about 73 % of the control level. Therefore both 
PARP and DNA flow cytometry show that caspases play a critical role in the 
DHA-mediated apoptosis in A375 cells. 
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General caspase inhibitor (jiiM) 0 0 40 40 100 100 
160 ^M DHA - + - + - + 
Active PARP (116 kDa) — W H t ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
Cleaved PARP (89 kDa) — ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
P-actin (42 kDa) — H m M P W t H V ^ B P 
Fig. 3.8 Representative Immunoblot Showing the Effect of General Caspase 
Inhibitor Pre-Incubation on DHA-Induced PARP Cleavage in A375 
Cells 
Melanoma cells pre-incubated for 1 h in the absence or presence of 40 or 
100 i^M general caspase inhibitor were treated with or without 160 |aM 
DHA for 72 h. Cell lysates were analyzed by Western blotting using a 
specific antibody for PARP. DHA induced PARP cleavage of melanoma 
cells, while pre-incubatioii with the general caspase inhibitor totally 
suppressed the DHA action, p-actin was included as loading control to 
normalize expressions of the PARP protein. 
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Fig. 3.9 Representative DNA Histograms Showing the Effect of General Caspase 
Inhibitor Pre-lncubation on DHA-Induced DNA Fragmentation in A375 
Cells 
Melanoma cells pre-incubated for 1 h in the absence or presence of 100 \iM 
general caspase inhibitor were treated with 160 |_iM DHA for 72 h, and were 
then subjected to flow cytometric analysis of DNA content using PI staining. 
Control that treated with vehicle only is also shown. Cells inside the gate 
harbor hypodiploid DNA content after DNA fragmentation and were defined 
as apoptotic cells. Apoptotic cells were counted and indicated, and their 
numbers are expressed as a percentage of total population. 
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S.L5 Caspase 3, 6, 8 and 9 were activated in DHA-induced apoptosis of A375 cells 
DHA-induced apoptosis of A375 cells is associated with caspase activations 
(Section 3.1.4). To find out which caspases had been involved, lysates from the 
DHA-treated A375 cells were immunoblotted with specific antibodies against 
different caspases, including the initiator caspase 8, 9，10 and the effector caspase 3, 6, 
7. 
During DHA-induced apoptosis, i.e. 160 [iM DHA treatment, procaspase 3, an 
effector caspase, was cleaved into the active p l9 /p l7 subunits while the level of 
procaspase 6, another effector caspase, was reduced (Fig. 3.10). Procaspases 8 and 9, 
the initiator caspases, were cleaved into active p43/p41 subunits and p37/p35 subunits, 
respectively (Fig. 3.10). This suggested that both the extrinsic and intrinsic apoptosis 
pathways had been elicited by DHA in A375 cells. The effector caspase 3 and 6 were 
probably activated by the initiator caspases. 
To verify the roles of caspases in DHA-induced apoptosis, the melanoma cells 
were treated with selective caspase inhibitors (caspase 3, 8 and 9-targeted) prior to 
DHA incubation and the PARP status of the cells were compared by immunoblotting. 
Previous results showed that 160 ^iM DHA induced PARP cleavage, leading to 
apoptotic cell death, which was accompanied by the cleavage or depletion of 
procaspase 3, 6, 8 and 9. Fig. 3.11 shows that DHA-induced PARP cleavage may 
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partially inhibited after pre-inciibation with caspase 8 or 9 inhibitor, indicating that 
both caspases 8 and 9 may contributed to initiate the DHA-induced apoptosis. In 
addition, since caspase 3 inhibitor could only partially rescue the PARP cleavage, 
















































































































































































































































































































































































































































































































































































































































































































3.1.6 DHA dissipated mitochondrial membrane potential in A375 cells 
Caspase 9, the initiator caspase of mitochondrial pathway of apoptosis, was 
found to be activated during the DHA-induced apoptosis (Fig. 3.10). Mitochondrial 
membrane depolarization, which occurs in the earlier stage of mitochondrial pathway 
of apoptosis, can be detected when the mitochondria permeability transition pores are 
open, resulting in the free distribution of ions between both sides of the membrane 
(Gross et al., 1999). Therefore, to further determine the effect of DHA on initiating 
the mitochondrial pathway of apoptosis, mitochondrial membrane potential (A^Pm) in 
A375 cells was measured after DHA treatment. 
Flow cytometry using TMRE, a potential-sensitive fluorescent probe, was 
employed to study the mitochondrial membrane potential. Fig. 3.12 shows the 
percentage of melanoma cells with reduction in mitochondrial membrane potential 
treated with different doses of DHA for 72 h. DHA induced mitochondrial membrane 
depolarization dose-dependently so that more than 73 % of the cells had 
depolarization at 160 |aM DHA treatment, by which PARP cleavage (Fig. 3.7) and 




















































































































































































































































































































































































3.1.7 DHA triggered the mitochondrial pathway of apoptosis 
Mitochondrial membrane depolarization was observed in melanoma cells 
incubated with DHA (Fig. 3.12). Apoptosis via the mitochondrial pathway involves 
permeabilization of the outer mitochondrial membrane, which is responsible for the 
release of cytochrome c and other apoptogenic molecules. This essential step is under 
the control of the Bcl-2 family proteins (Chipuk et al., 2006). Therefore, some of the 
Bcl-2 family protein expressions were measured in DHA treated A375 cells. Eight 
better characterized Bcl-2 family proteins were studied, including antiapoptotic Bcl-2, 
Bcl-xi, and Mcl - l , and proapoptotic Bad, Bak, Bax, Bid and Bim. 
Antiapoptotic Bcl-2, BC1-XL and Mcl-l inhibit release of cytochrome c and 
other mitochondrial membrane events during apoptosis (van Delft and Huang, 2006). 
Fig. 3.13 and Table 3.2 show that DHA reduced Bcl-2 expression at 160 |LIM, while 
the expressions of BC1-XL and Mcl-l remained constant after DHA incubation. 
On the other hand, proapoptotic Bcl-2 family proteins inhibit activity of the 
antiapoptotic members and also promote the release of cytochrome c and thus activate 
initiator caspases (Strasser et a I., 2000). 160 | iM DHA reduced expression level of the 
proapoptotic member Bak, while the expression levels of other proapoptotic proteins 
were unchanged or decreased (Fig. 3.13, Table 3.2). 
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Bak (25 kDa) - —— 
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Fig. 3.13 Representative Immunoblots Showing the Effects of DHA on the 
Expression Levels of Bcl-2 Family Proteins in A375 Cells 
Lysates from DHA-treated A375 cells were analyzed for protein levels of 
eight Bcl-2 family members by Western blotting using specific antibodies. 
P-actin was included as loading control. The expression level of 
antiapoptotic Bcl-2 protein was decreased in DHA-treated cells, while that 
of proapoptotic Bak protein was increased. Expression of other Bcl-2 family 
proteins did not change. Interestingly, proapoptotic Bad and BiiiiEL were 
also decreased after DHA treatment. 
69 
Table 3.2 Numeric Data Showing the Effects of DHA on Bcl-2 and Bak 
Expressions in A375 Cells 
Control 160 \iM DHA 
Bcl-2 / p-actin ratio 0.19 土 0.06 0.11 士 0.02 
Bak / p-actin ratio 0.15 士 0.03 0.26 士 0.08 
The protein expression level, in terms of banding density, was measured 
using image analysis software, and the results are expressed as mean of the 
protein/p-actiii ratio 士 S.D (n=3). Difference in means between the control 
and treatment groups was compared by Student's /-test. 160 |iM DHA 
appeared to decrease antiapoptotic Bcl-2 (j? = 0.129) and increase 
proapoptotic Bak (/; = 0.132) expression at 72 h of incubation. 
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3.1.8 DHA triggered the death receptor pathway of apoptosis 
Besides caspase 9，caspase 8, the initiator caspase of the death receptor 
pathway of apoptosis, was found to be activated in DHA-induced apoptosis in the 
melanoma cells (Fig 3.10). The death receptor on the cell surface triggers the death 
signal, which in turn activates caspase 8. One possible death signal is triggered by 
TNF-related apoptosis inducing ligand (TRAIL) and its receptor DR4 (Pan et al., 
1997). 
Expressions of TRAIL and DR4 in the DHA-treated cells were investigated. 
Both the ligand and receptor expressions were upregulated after treating with DHA, 
especially at 160 ^iM treatment (Fig. 3.14, Table 3.3) that prominent PARP cleavage 
(Fig. 3.7) and apoptosis occurred (Fig. 3.5). This indicated that DHA might turn on 
the death receptor pathway probably by upregulating the expression of DR4 and 
TRAIL inA375 cells. 
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Fig. 3.14 Representative Immunoblots Showing the Effects of DHA on Protein 
Expressions of TRAIL and DR4 in A375 Cells 
Lysates from DHA-treated A375 cells were analyzed for protein levels of 
DR4 and TRAIL by Western blotting using their specific antibodies, p-actin 
was included as loading control. DHA increase the protein levels of DR4 
and TRAIL dose-dependently. 
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Table 3.3 Numeric Data Showing the Effects of DHA on TRAIL and DR4 
Expressions in A375 Cells 
0 nM DHA 160 [iM DHA 
DR4 / p-actin ratio 0 . 0 9 士 0.01 0 . 2 8 土 0 . 0 5 * 
TRAIL / p-actin ratio 0.25 土 0.03 0.44 ± 0.12 
Numeric data of the expression level of DR4 and TRAIL are shown. It was 
measured using image analysis software and the results are expressed as 
mean density of the proteiii/p-actin ratio 土 S.D (n二3). Difference in means 
between the control and treatment groups was compared by Student's /-test， 
*p < 0.05. 160 fiM DHA increased the expression levels of DR4 and TRAIL 
(/) = 0.108). 
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3.2 In vivo study of the anticancer effect of DHA on A375 cells 
3.2.1 Effect of DHA on the growth ofA3 75 xenograft in a thymic Balb/c mice 
Since human xenograft model is one of the best models for predicting drug 
efficacy in clinical settings, antitumor activity of DHA against A375 xenograft in 
athymic nude mice was examined. The mice bearing A375 solid tumors were treated 
orally by gavage with different doses of DHA once daily for 10 consecutive days. At 
the end of treatment period, the tumors were excised and measured for their weights. 
The mice are shown in Fig. 3.15. DHA induced tumor regression significantly (Fig. 
3.16). DHA reduced the tumor weight significantly by 57.1 and 61.9 % of the control 
level at 50 and 200 mg/kg, respectively. 
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Fig. 3.15 Photographs Showing Athymic Balb/c Mice Bearing A375 Solid Tumor 
Treated with Different Dosages of DHA 
Athymic Balb/c mice were inoculated with human melanoma A375 cells 
SLibcutaneously. Ten days after inoculation, the tumor-bearing mice were 
divided into four groups, receiving 0, 12.5, 50 and 200 mg/kg body weight 
of DHA by gavage respectively for 10 consecutive days. The solid tumors 
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Fig. 3.16 Effect of DHA on the In Vivo Growth ofA375 Xenograft in Nude Mice 
Results are expressed as mean tumor weight 土 S.D (n=6). Difference in 
means between the control and treatment groups was compared by Student's 
/-test, */) < 0.05. DHA reduced the tumor weight significantly by 57 and 61 
% of the control level at 50 and 200 mg/kg, respectively. 
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3.2.2 DR4 and TRAIL were upregulated by DHA treatment in A3 75 solid tumor 
As indicated in the previous in vitro studies, DHA modulated the protein 
expressions of Bcl-2, Bak, DR4 and TRAIL in A375 cells, which were associated with 
reduced proliferation and viability of the melanoma cells. In addition to the in vivo 
growth inhibition on A3 75 xenograft, Bcl-2, Bak, DR4 and TRAIL expressions in the 
solid tumor after DHA treatment were also examined (Fig. 3.17). Similar to the 
findings from in vitro studies, 50 mg/kg DHA seemed to decrease Bcl-2 level and to 
increase Bak and TRAIL expression, although the changes could not attain 
statistically significant level. Similar to the in vitro finding, DHA also elevated DR4 
level in vivo so that the protein increased significantly (p < 0.05) by about 1.9-fold of 
the control level. 
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Bcl-2 (26 kDa) — m m m m 如 • 铺 M i 
1.44 ± 1.05 0.94 ±0.61 
Bak (25 kDa) ™ — 一 一 一 
0.29 ± 0.15 0.32 ±0.11 
DR4 (56 kDa) — 二 一 一 
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TRAIL (32 k D a ) - — — 一 — — — 一 
0.24 ±0 .12 0.72 ±0 .42 
p-actin (42 kDa) - mmm mmmm mtam w m ^ , 
Fig. 3.17 Immunoblots Showing the In Vivo Effects of DHA on Apoptosis-Related 
Protein Expressions in A375 Solid Tumor 
Lysates were prepared from A375 xenografts in Balb/c mice that had been 
treated with or without 50 mg/kg DHA, and were then analyzed for protein 
levels of Bcl-2, Bak, DR4 and TRAIL by Western blotting using specific 
antibodies. (3-actin was included as loading control. The density of each 
band was measured using image analysis software. Numeric data expressed 
as mean density of the proteiii/p-actin ratio 土 S.D. is shown below each 
immunoblot. Difference in means between the control and treatment group 
was compared by Student's 广-test,尔p < 0.05. Similar to the in vitro findings, 
DHA seemed to decrease Bcl-2 but to increase Bak and TRAIL levels, 
although the changes were not statistically significant. Interestingly, both in 
vitro and in vivo studies illustrated that DHA increased DR4 level in A375 
cells. 
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Chapter 4 Discussion 
Cancer afflicts all communities. It is a disease that involves a pathological 
breakdown in the processes which control cell proliferation, differentiation and death 
of particular cells. The principle modes of therapy are surgery, radiotherapy and 
chemotherapy; which are given alone or in combination. At present, only a few 
chemotherapeutic drugs are effective in the treatment of human cancers, mainly due to 
the high toxicity, lack of specificity and rapid development of chemoresistance in the 
others. Therefore, continual searching for new chemotherapeutic agents is needed. 
In recent years, natural products are of increasing interest as anticancer agents, 
particularly those found in foods. Increasing evidence from animal and in vitro studies 
indicates that omega-3 polyunsaturated fatty acids (co-3 PUFAs), especially the 
long-chain PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
present in fatty fish and fish oils inhibit carcinogenesis and suppress cancer cell 
growth. Several studies have shown that DHA inhibits proliferation and/or induces 
apoptosis of several human cancer cells, including colon, breast and prostate cancers 
(Calviello et cd., 2004; Chen and Istfan, 2000; Chiu et al” 2004a; Chung et al., 2001; 
Hofmanova et al., 2005; Narayanan et aL, 2001, 2003, 2004, 2005). DHA as an 
anticancer agent is worth to be explored because it can be acquired at relatively low 
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costs compared to many new chemotherapeutic agents which are often of high costs 
(Kleihues et al., 2003). DHA can be easily obtained from marine animals. Since fish 
may not be the best source of DHA, much effort is now being devoted to reduce the 
cost of biomass production of microalgae with high content of DHA (Cohen et al, 
1995; Gill and Valivety, 1997). Large scale production using microalgae as the 
bioreactor may provide a more economic source of DHA with consistent quality and 
quantity. In addition, DHA did not show toxicity to normal cells (Begin et al., 1985). 
Understanding the mechanisms responsible for the antiproliferative and cytotoxic 
activities of DHA on cancer cells may provide evidence for future development of 
DHA in clinical uses as a cancer therapeutic agent which is of low cost and has less 
side effects. 
In the present study, the inhibitory activity of DHA on cell proliferation and 
viability was evaluated in five cancer cell lines from different organ sites and 
histological subtypes by using MTT assay. MTT assay is an economical and rapid 
method for preliminary screening of the growth inhibitory effect of DHA by 
measuring cell proliferation and death simultaneously in terms of the level of cellular 
metabolic activity. Growth of all cancer cells tested in this study was inhibited by 
DHA dose-dependently. A375 melanoma was found to be the most responsive cell 
line to the DHA treatment. 
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At present, no effective treatment exists for metastatic melanoma (Kleihues et al.’ 
2003). DHA as a potent inhibitor of A375 melanoma cells may be a potential 
candidate for the treatment of metastatic melanoma. Therefore, A375 melanoma cell 
line was chosen for detailed analysis. Since tumor growth is at least partially a 
balance between cell proliferation and death, a number of studies were performed to 
determine the effects of DHA on these events in order to identify the mechanisms for 
the induced growth inhibition. 
To further investigate the cytostatic effect of DHA on the melanoma cells, BrdU 
incorporation in the cells was measured after incubation with different concentrations 
of DHA. BrdU is an analogue of pyrimidine and its incorporation to the cellular DNA 
is a measure of cell proliferation. The decrease in BrdU incorporation after DHA 
treatment implied that the fatty acid had retarded the A375 cell proliferation. DHA 
inhibited the growth of A375 cells dose-dependently. We are the pioneer group to 
show that DHA can retard growth of melanoma cells. 
Afterwards, DNA-flow cytometry was used to further examine the effect of DHA 
on the cell cycle distribution as well as the death of A375 cells. Cell cycle proceeds by 
well-defined successive steps, each of which must be completed before beginning of 
next one. It comprises four phases: Gi (first gap), S (DNA synthesis), G2 (second gap) 
and M (mitosis). Analysis of the cell cycle phase distribution of A375 cells after 
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treating with DHA for 72 h revealed that DHA had two effects on the melanoma cells. 
Low doses (below 80 |iM) of DHA induced cell cycle arrest at G2/M and S phase, 
while 160 ^iM DHA not only arrested cells in G2/M and S phase, but also induced 
apoptosis. The prolonged arrest at G2/M and S phase might have induced some of the 
arrested cells to undergo apoptosis. Siddiqui et al. (2003) also found that low doses of 
DHA induced growth inhibition in Jurkat cells by inducing cell cycle arrestment. The 
cells were arrested in S phase probably through hypophosphorylatioii of pRb by 
inhibiting cdk2 and stimulating protein phosphatase activities. Furthermore, repeated 
low doses of DHA induced apoptosis via activation of caspase 3 (Siddiqui et al., 
2003). 
DHA not only inhibited proliferation of the melanoma cells but also induced cell 
death. There are two different modes of cell death: necrosis and apoptosis. Necrosis is 
a passive process which is induced mainly by mechanical or chemical injury. In 
contrast, apoptosis is an active process which occurs in response to specific 
stimulations and is tightly regulated by genes controlling cell death. Apoptosis 
induction is an important cancer therapeutic route since aberrations in apoptotic 
pathways have been detected in a variety of cancers. Better understanding of the 
processes involved in apoptosis might lead to improved treatment regimens. 
Apoptosis is characterized as a well-ordered, programmed sequence of events of cell 
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death involving the loss of mitochondrial membrane potential through the action of 
Bcl-2 family proteins, caspase activation, and DNA fragmentation. 
According to the results of DNA-flow cytometry in the present study, apoptosis 
was detected in the A375 cells, in terms of hypodiploid DNA content in cells, in 160 
|iM DHA treatment. In addition, PARP cleavage was also observed in the Western blot 
analysis which consolidates the finding that DHA induced apoptosis in the melanoma 
cells. PARP is important for cells to maintain their viability, cleavage of which 
facilitates cellular disassembly and serves as a marker of cell apoptosis (Kaufmann et 
a I., 1993). The cleavage of PARP also indicates that caspases might be involved in 
DHA-induced apoptosis since cleavage of PARP is resulted from the activation of 
caspases. To confirm this observation, general caspase inhibitor was employed. The 
DHA-induced PARP cleavage in A375 cells was totally inhibited after treatment with 
general caspase inhibitor. However, the DHA-induced DNA fragmentation was not 
entirely recovered by the caspase inhibitor. This suggested that the DHA-induced 
apoptosis in the melanoma cells might be mediated by both caspase-dependent and 
caspase-independent events. 
The central part of the current study is to elucidate the apoptotic pathways 
induced by DHA in A375 cells. There are two better-characterized pathways of 
apoptosis, the intrinsic mitochondrial and extrinsic death receptor pathways. The 
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upstream initiator caspases, caspase 8 and 10 in the extrinsic pathway and caspase 9 
in the intrinsic pathway, converge the apoptotic signals to the downstream effector 
caspases, which in turn execute cell death. Results from the Western blot analysis 
showed that both of these pathways were activated upon treatment with DHA, as 
indicated by cleavage and thus activation of caspase 8 and caspase 9. Preincubation 
with either caspase 8 or 9 inhibitor could only partially retard the DHA-induced PARP 
cleavage, suggesting that their activations are initiated independently. This could be 
further proved by the presence of intact Bid protein after DHA treatment. Bid is a 
BH3 domain-only protein, which is localized in the cytosol of cells as an inactive 
precursor. Cytosolic Bid can be cleaved by caspase 8 or 10 in the death receptor 
pathway. Its active form, truncated Bid (tBid), is able to translocate to mitochondria 
and sensitizes cytochrome c release, thus activating the mitochondrial pathway. Bid 
serves as a cross-talk protein between the extrinsic and intrinsic apoptotic pathways 
(Li et al, 1998). Therefore, the two pathways might be activated independently. 
The caspase 9 activation and dissipation of the mitochondrial membrane 
potential illustrated that the intrinsic apoptotic pathway in A375 cells was elicited by 
DHA treatment. The Bcl-2 family proteins are the central regulators of the intrinsic 
pathway. Mitochondrial membrane permeabilization leading to the release of 
cytochrome c and other apoptogenic molecules is under the control of the Bcl-2 
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family proteins. Immunoblot studies illustrated that the DHA-induced apoptosis was 
associated with the depletion of antiapoptotic Bcl-2 protein and the increased 
expression of proapoptotic Bak protein. Bcl-2 is localized on the mitochondrial 
membrane which inhibits release of apoptogenic factors from mitochondria by several 
' mechanisms, including inhibition of proapoptotic Bax translocation from the 
cytoplasm to mitochondria and trapping of activated proapoptotic Bcl-2 family 
proteins (Bonier, 2003). The ratio of Bcl-2 to Bax within a cell is the critical 
determining factor for the propensity of the cell to undergo apoptosis (Oltval et al., 
1993). Although the expression level of Bax is more or less the same after treating 
with DHA in the present study, the ratio of Bcl-2 to Bax in the melanoma cells was 
decreased, and may thus promote apoptosis. This finding is similar to the apoptosis in 
HT-29 colon cancer cells, in which DHA decreased Bcl-2 level with an increased 
sensitivity to lipid peroxidation but did not change the level of Bax (Chen and Istfan 
2000). On the other hand, Bak is a proapoptotic protein which can bind to 
antiapoptotic members, such as BCI-XL, to neutralize their antiapoptotic ability. 
Furthermore, Bak is similar to Bax which can oligomerize and form pores to perturb 
the outer mitochondrial membrane to release apoptogens. Increased expression of Bak 
was also found in the DHA-induced apoptosis of colo-201 cells, which was 
accompanied with the depletion of B c l - 2 and BC1-XL (Danbara et al” 2 0 0 4 ) . High 
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expression of Bcl-2 has been correlated with decreased survival and resistance to 
chemotherapy in human melanomas and other tumors (Helmbach el a!., 2001; 
Soengas and Lowe, 2003). DHA-induced downregiilation of Bcl-2 protein and 
Lipregulation of Bak protein may lead to an increase in apoptosis or at least in the 
responsiveness of the melanoma cells to apoptotic stimuli. In addition to Bcl-2 family 
proteins, the mitochondrial dysfunction in A375 cells may be directly affected by 
DHA. Omega-3 PUFAs have been reported to alter mitochondrial membrane 
properties and functions in several cancer cells of human and rat (Siddiqui et aL, 
2004). Evidence has suggested that DHA preferentially accumulates in cardiolipin 
(CL). CL is a diphospholipid required for mitochondrial structure integrity and proper 
functioning of the electron transport chain. CL is only present in the mitochondrial 
membrane，and is situated in the inner membrane and intermembrane contact sites. 
The mitochondrial function is very much dependent on the proper amount of CL. It is 
believed that DHA in CL is susceptible to reactive oxygen species (ROS), which are 
generated through oxidative phosphorylation. CL is peroxidized by ROS and thus 
results in a decrease in CL level in the mitochondrial membrane. It has been suggested 
that low level of CL, either by peroxidation or its decreased synthesis, compromises 
the integrity of CL-dependent proteins involved in energy metabolism, causing a drop 
in the mitochondrial membrane potential, which in turn initiates apoptosis (McMillin 
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and Dowhan, 2002). Further studies are required to determine if DHA also induces 
apoptosis in A375 cells via this route. 
As shown ill this study, besides the intrinsic pathway, DHA also triggered the 
extrinsic apoptotic pathway in the melanoma cells. Initiator caspase 8 in the death 
receptor pathway was activated upon DHA treatment. Activation of caspase 8 was 
probably triggered by the death receptor DR4, since increased expression of DR4 and 
its ligand TRAIL was found in the melanoma cells. DR4, belongs to the TNF receptor 
superfamily, is a major player for TRAIL sensitivity in melanoma cells; cells lacking 
or with low level of DR4 showed reduced sensitivity or resistant to TRAIL-induced 
apoptosis (Kim et al., 2000). In addition, overexpression of DR4 may trigger cells to 
undergo ligand-independeiit apoptosis (Pan et al., 1997). Vaciilova et al. found that 
DHA could sensitize HT-29 colon cancer cells to TRAIL-mediated apoptosis 
(Vaculova et al., 2005). Hence, in this study, DHA may sensitize melanoma cells to 
TRAIL-mediated apoptosis through upregulating DR4 expression. Moreover, 
DHA-induced TRAIL expression is important as TRAIL only induces apoptosis in 
malignant cells, including melanoma cell lines, but not normal tissues (Zhang el ciL, 
1999). 
In the first part of this study, DHA was found to retard the growth of human 
melanoma A375 cells in vitro. Prior to clinical trials, it is essential that the in vivo 
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efficacy of potential anticancer agents has been determined in a suitable animal model. 
Immunosuppressed mice with subcutaneous implantation of human tumor xenografts 
have played a significant role in the preclinical development of anticancer drugs in the 
past years. In view of this, melanoma A375 cells were implanted into nude mice to 
study the anticancer effect of DHA in vivo. A number of previous studies have shown 
that co-3 PUFAs inhibit or prevent the growth of several types of tumor in animal 
models (Braden and Carroll, 1986; Cave, 1991; Rao et al” 2001; Reddy and 
Maruyama, 1986; Wii et al, 2005). However, usually crude vegetable or marine oils, 
which usually consisted of a mixture of different PUFAs, were employed for 
investigation. In addition, there is no information about the effect of DHA on 
melanoma growth in vivo. Here, we used high purified DHA from a microalga (purity 
> 98 o/o) to investigate its effect on human melanoma A375 xenograft in nude mice. 
DHA, at a dose of 50 mg/kg, was found to induce tumor regression significantly, 
accompanied with elevated DR4, TRAIL and Bak expression and decreased Bcl-2 
expression in the tumors. The results of this in vivo study correlate well with those of 
the in vitro study. No observable adverse effect was found. 
This in vivo study provides a foundation for the future development of DHA as a 
chemotherapeutic agent, possible with less severe side effect. However, since it has 
been reported that dietary supplementation with large amount of co-3 fatty acids may 
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have detrimental effects on humans (Palozza et al., 1996; Burns et al., 2004), the 
safety issues of using DHA as an anticancer agent should be studying in more details 
in later studies. Palozza et al. (1996) found that long-term (180 days) supplementation 
with high dose of co-3 PUFAs (4.1 g EPA plus 3.6 g DHA per day) induced complex 
oxidative and metabolic changes in human red blood cell (RBC) membranes by 
modulating fatty acid composition and a-tocopherol content, and altering membrane 
susceptibility to oxidative stress. The increased susceptibility to lipid peroxidation 
observed in the RBC membranes might also indicate that oxidative modifications had 
occurred in plasma low density lipoproteins (LDLs). Alteration of LDL by oxidation 
of their PUFA components has been implicated in the etiology of atherosclerosis. On 
the other hand, short-term (30 days) supplementation with high dose of (o-3 PUFAs 
protected red blood cells from lipid peroxidation (Palozza et al., 1996). In a phase II 
clinical study of fish oil capsules, 0.15 g/kg of co-3 PUFAs was daily administered to 
patients with malignancy-related cachexia (Bums et al., 2004). Patients were found to 
have gastrointestinal side effects but not other severe life-threatening conditions. In 
our study, mice were only treated with DHA for a short-term (10 days) only, and the 
significant dose (0.05 g/kg DHA) for tumor regression was lower than those studied 
by Palozza and Bums, thus this regimen may be applicable to human with less side 
effects. In addition, a phase I clinical study reported that the maximum tolerated dose 
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(MTD) of fish oil fatty acids in patients with cancer cachexia was 0.3 g/kg per day 
(Burns et al., 1999). The significant dosage used in our study was less than the MTD. 
However, a definite conclusion in the safety issues of using pure DHA as a 
chemotherapeutic agent in human cannot be drawn yet because a mixture of co-3 
PUFAs was used in the studies mentioned above. Nevertheless, further studies on the 
pharmacokinetics and pharmacodynamics of DHA in laboratory animals are required 
before clinical trials on humans should begin. 
In conclusion, DHA retards growth and induces cell death in A375 melanoma 
cells both in vitro and in vivo. It activates both the intrinsic and extrinsic apoptotic 
pathways by modulating several apoptotic proteins, Bcl-2, Bak, DR4, and TRAIL. 
These proteins have been reported to play significant roles in chemoresistaiice in 
melanomas. More melanoma cell lines, both malignant and non-malignant cells, 
should be included in future studies to obtain more comprehensive and conclusive 
results so as to estimate the anticancer efficacy of DHA on melanomas. Although 
there is no known toxicity of DHA in normal cell cultures, further investigations on 
the safety issues of DHA should be conducted. Nevertheless, this study may provide a 
foundation for the further development of DHA as a potential chemotherapeutic agent. 
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